| Are cardiovascular benefits in statin lipid effects dependent on baseline lipid levels? | |
| | |
MedLine Citation:
|
PMID: 21104458 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Statins reduce coronary heart disease (CHD) morbidity and mortality over a wide range of patients. The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) in subjects with elevated C-reactive protein, without vascular disease and below average low-density lipoprotein cholesterol (LDL-C) showed a 50% reduction in LDL-C with 20 mg/d of rosuvastatin and a reduction in cardiovascular events (hazard ratio 0.56 [95% CI, 0.46-0.69]; P < 0.00001), and a reduction in total mortality (20%; P < 0.02). Recent commentary has criticized perceived JUPITER design flaws and inappropriate influence. However, the Canadian 2009 guidelines cite JUPITER as class I evidence for statin benefit. Although the Cholesterol Treatment Trialists' (CTT) Collaborators showed that, regardless of pre-treatment levels, statins can significantly reduce CHD, major vascular events, and overall mortality, a recent primary prevention meta-analysis showed no decrease in all-cause mortality. Preconceived notions on statin benefit or harm do not enhance patient care and clinicians should individualize long-term statin therapy. |
| | |
Authors:
|
Keith C Ferdinand |
Related Documents
:
|
12635468 - Simvastatin and pravastatin equally improve flow-mediated dilation in males with hyperc... 19681658 - Antiatherogenic effect of simvastatin is not due to decrease of ldl cholesterol in ovar... 19589008 - Lipid profile changes associated with changing available formulary statins: removing hi... 12492458 - Treatment with atorvastatin alters the ratio of interleukin-12/interleukin-10 gene expr... 11383688 - Lipid and fatty acid profiles in rats consuming different high-fat ketogenic diets. 19494768 - Body composition determination by bioimpedance: an update. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current atherosclerosis reports Volume: 13 ISSN: 1534-6242 ISO Abbreviation: Curr Atheroscler Rep Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-01-11 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897685 Medline TA: Curr Atheroscler Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 64-72 Citation Subset: IM |
Affiliation:
|
Division of Cardiology, Emory University, 5355 Hunter Rd., Atlanta, GA 30349, USA. kferdinand@abcardio.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inhibition of Endogenous Hydrogen Sulfide Generation is Associated with Homocysteine-Induced Neuroto...
Next Document: Fisher syndrome.